A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

In this article, the authors discuss a placebo-controlled trial of fingolimod in patients with relapsing multiple sclerosis (MS). They say that the study assessed fingolimod's efficacy in 1272 relapsing-remitting MS (RRMS) patients, who randomly received oral fingolimod capsules at doses of 0.5 milligrams (mg) or 1.25 mg per day. They conclude that the doses were as effective in RRMS treatment as in placebo, but note that the benefits of fingolimod must be balanced against potential risks.